Features Partner Sites Information LinkXpress
Sign In
Demo Company

Luteolin Nanocapsules Demonstrate Effective Anticancer Activity in Mouse Model

By BiotechDaily International staff writers
Posted on 23 Jan 2014
Print article
Image: Cellular uptake of nanoparticles encapsulating both dye and luteolin (Photo courtesy of Winship Cancer Institute of Emory University).
Image: Cellular uptake of nanoparticles encapsulating both dye and luteolin (Photo courtesy of Winship Cancer Institute of Emory University).
Nanocapsules containing the natural antioxidant luteolin were found to be significantly more effective than natural luteolin in inhibiting growth of cancer cells both in culture and in a mouse xenograft model.

Luteolin is a flavone, a type of flavonoid, and, like all flavonoids, has a yellow crystalline appearance. Dietary sources include celery, green pepper, thyme, dandelion, chamomile tea, carrots, olive oil, peppermint, rosemary, navel oranges, and oregano. Luteolin reportedly acts as a monoamine transporter activator, and is one of the few chemicals demonstrated to possess this property. Experiments have suggested that luteolin may inhibit the development of some types of skin cancer.

In the current study, investigators at Emory University (Atlanta, GA, USA) formulated water-soluble polymer-encapsulated Nano-Luteolin from luteolin, and studied its anticancer activity against lung cancer and head and neck cancer. The low water solubility of luteolin, which hampers its use in treatment due to problems of low bioavailability, poor systemic delivery, and low efficacy, led the investigators to choose a nanocapsule format for their experiments.

Results published in the January 2014 issue of the journal Cancer Prevention Research revealed that like luteolin, Nano-Luteolin inhibited the growth of lung cancer cells (H292 cell line) and squamous cell carcinoma of head and neck (SCCHN) cells (Tu212 cell line). In vivo studies using a tumor xenograft mouse model demonstrated that Nano-Luteolin had a significant inhibitory effect on the tumor growth of SCCHN in comparison to luteolin.

"Our results suggest that nanoparticle delivery of naturally occurring dietary agents like luteolin has many advantages," said senior author Dr. Dong Moon Shin, professor of hematology and medical oncology at Emory University. "By using a high concentration of luteolin in the blood, we were better able to inhibit the growth of cancer cells."

Related Links:

Emory University

Print article



view channel
Image: Left: Green actin fibers create architecture of the cell. Right: With cytochalasin D added, actin fibers disband and reform in the nuclei (Photo courtesy of the University of North Carolina).

Actin in the Nucleus Triggers a Process That Directs Stem Cells to Mature into Bone

A team of cell biologists has discovered why treatment of mesenchymal stem cells (MSCs) with the mycotoxin cytochalasin D directs them to mature into bone cells (osteoblasts) rather than into fat cells... Read more


view channel

Molecular Light Shed on “Dark” Cellular Receptors

Scientists have created a new research tool to help find homes for orphan cell-surface receptors, toward better understanding of cell signaling, developing new therapeutics, and determining causes of drug side-effects. The approach may be broadly useful for discovering interactions of orphan receptors with endogenous, naturally... Read more

Lab Technologies

view channel
Image: The new ambr 15 fermentation micro-bioreactor system was designed to enhance microbial strain screening applications (Photo courtesy of Sartorius Stedim Biotech).

New Bioreactor System Streamlines Strain Screening and Culture

Biotechnology laboratories working with bacterial cultures will benefit from a new automated micro bioreactor system that was designed to enhance microbial strain screening processes. The Sartorius... Read more


view channel

Purchase of Biopharmaceutical Company Will Boost Development of Nitroxyl-Based Cardiovascular Disease Drugs

A major international biopharmaceutical company has announced the acquisition of a private biotech company that specializes in the development of drugs for treatment of cardiovascular disease. Bristol-Myers Squibb Co. (New York, NY, USA) has initiated the process to buy Cardioxyl Pharmaceuticals Inc. (Chapel Hill, NC, USA).... Read more
Copyright © 2000-2015 Globetech Media. All rights reserved.